Reata Pharmaceuticals, Inc. Submits NDA for Company ’s Lead Program: Bardoxolone in Alport Syndrome

PLANO, Texas, March 01, 2021 (GLOBE NEWSWIRE)— Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the“Company,” or“we”), a clinical-stage biopharmaceutical company, today announced...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news